title: Bacillus Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals.
abstract: BACKGROUND
  The World Health Organization (WHO) has recommended Bacillus Calmette-Guerin (BCG) vaccination as a part of the global expanded program for immunization. Although the BCG vaccine is usually a safe vaccine, a number of complications with lymphadenitis being the most common complication, can occur.
  
  
  OBJECTIVE
  We evaluated the frequency, the clinical presentation and treatment modalities of lymphadenitis after BCG vaccine in Saudi children.
  
  
  RESULTS
  A total of 145 patients with BCG lymphadenitis presented between January 2005 and December 2010. In the majority (103) of the cases, the lymphadenitis involved ipsilateral left axillary nodes. Other sites of involvement included the left supraclavicular lymph nodes in 26 (18%) patients, and both the left axillary and supraclavicular lymph nodes were involved in 7 cases (4.8%). A total of 75 patients (65%) were given antituberculous medication. Eight (27%) patients had positive acid-fast bacilli and positive cultures for Mycobacterium bovis.
  
  
  CONCLUSIONS
  In light of the findings of this study, it would be advisable to administer the BCG vaccine in Saudi Arabia at a time later than at birth, as the younger children are commonly affected.
authors: Department of Pediatrics, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
authors: E
authors: E
authors: Bukhari
authors: M
authors: M
authors: Alzahrani
authors: S
authors: S
authors: Alsubaie
authors: A
authors: A
authors: Alrabiaah
authors: F
authors: F
authors: Alzamil
mesh_terms: D000367:Age Factors; D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology; D006761:Hospitals; D006801:Humans; D007223:Infant; D008199:Lymphadenitis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology* / Q000473:pathology; D008297:Male; D009163:Mycobacterium bovis / Q000302:isolation & purification*; D015995:Prevalence; D012529:Saudi Arabia / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents; D001500:BCG Vaccine